Compare Cigna Corp (CI) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cigna Corp vs BIO-TECHNE Corp — how do they compare? Cigna Corp trades at $302.59 (market cap $80.55B), while BIO-TECHNE Corp trades at $71.23 (market cap $11.12B). The key difference: Cigna Corp is far larger — about 7.2× BIO-TECHNE Corp's market cap, and Cigna Corp pays the higher dividend (2.05%). Which is the better fit depends on your goals.
| CI | TECH | |
|---|---|---|
Market Cap | $80.55B | $11.12B |
Sector | Health | Health |
52-Week High | $311.00 | $71.38 |
52-Week Low | $244.41 | $43.31 |
Enterprise Value | $103.65B | $11.20B |
Dividend Yield | 2.05% | 0.45% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cigna Corp
Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM services were greatly expanded by its 2018 merger with Express Scripts and are mostly sold to health insurance plans and employers. Its largest PBM contract is the Department of Defense. In health insurance and other benefits, Cigna mostly serves employers through self-funding arrangements, but it also operates in government programs, such as Medicare Advantage. The company operates mostly in the U.S. with 15 million medical members covered as of the end of 2020, but its services extend internationally, covering another 2 million people.
Read more on CI →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
